-
ThinkEquity Upgrades ITMN After FDA Approval
Wednesday, March 10, 2010 - 10:33am | 54Read More...Analysts at ThinkEquity Partners upgrade InterMune (NASDAQ: ITMN) from "hold" to "buy." According to ThinkEquity Partners, the upgrade in the rating follows the FDA approval of InterMune's Esbriet. ITMN’s shares closed at $23.30 yesterday. More Analyst Ratings here
-
ThinkEquity Downgrades FSLR On Potential Pricing Competition
Friday, February 19, 2010 - 11:11am | 80Read More...ThinkEquity downgraded First Solar (NASDAQ: FSLR) from “buy” to “hold.” The target price has been reduced from $162 to $114. According to ThinkEquity, FSLR is dependent on the internal systems business and exposed to currency fluctuations. The company is also likely to face pricing competition in...
-
SXC Health Solutions Upgraded To Buy
Wednesday, February 10, 2010 - 9:54am | 49Read More...Analysts at ThinkEquity upgrade SXC Health Solutions Corp (NYSE: SXC) from "hold" to "buy." The target price for SXC is set to $55. SXC’s shares closed at $49.45 yesterday. Read more about the market
-
ThinkEquity Puts PAR On Hold
Friday, January 29, 2010 - 9:08am | 39Read More...ThinkEquity downgraded 3PAR (NYSE: PAR) from “buy” to “hold.” ThinkEquity expressed its concerns surrounding deceleration in PAR’s new customer revenue growth. After gaining 1.26% yesterday, PAR slumped 4.11% to $10.02 in pre-market trading.
-
Retail Sector Looks Attractive; JCrew (JCG) A Good Buy
Thursday, January 28, 2010 - 8:33am | 137Read More...John Fitzgibbons, partner and head of wealth management at ThinkEquity, shared his market outlook with CNBC. He said that he is maintaining a cautious approach towards the markets. According to him, investors are looking for a reinsurance about the spending ability of U.S. consumer. He stated that...
-
AAPL To Post Strength In iPhone, Mac Sales
Monday, January 25, 2010 - 11:29am | 134Read More...Analysts at ThinkEquity reiterate their “buy” rating on Apple Inc (NASDAQ: AAPL), while raising their estimates for the company. Apple is scheduled to report its F1Q10 results today after the market close. The analysts expect the company to post a solid quarter, with more than 20% sequential growth...
-
ELX Guidance Appears Conservative
Friday, January 22, 2010 - 3:57pm | 154Read More...Analysts at ThinkEquity reiterate their “buy” rating on Emulex Corp (NYSE: ELX) while raising their estimates for the company. ELX has announced its 2Q FY10 results marginally ahead of its guidance. The analysts believe that Emulex’s 3Q FY10 guidance “reflects management's caution ahead of a...
-
QLGC Estimates Down, But ThinkEquity Optimistic About Margins, FCF
Friday, January 15, 2010 - 11:40am | 135Read More...Analysts at ThinkEquity reiterate their “buy” rating on QLogic Corporation (NASDAQ: QLGC), while reducing their estimates for the company. The recent pre-announcements point to QLogic’s HBA share loss to Emulex Corp (NYSE: ELX). The analysts say, however, that the operating leverage in QLGC's model...
-
Sales Of Activision Blizzard’s (ATVI) MW2 Strong
Wednesday, January 6, 2010 - 12:39pm | 124Read More...The sales of Activision Blizzard’s (NASDAQ: ATVI) MW2 have been strong according to a report by ThinkEquity LLC. MW2 was one of the top selling titles of the holiday season according to the report. Analysts estimate sales of 14-15 million units in Q4 which is higher than their previous estimate of...
-
ZIKI Winds Down ePrescription Business
Friday, December 11, 2009 - 2:06pm | 105Read More...Analyst Jonathan Ruykhaver of ThinkEquity LLC maintains his "buy" rating on Zix Corporation (NASDAQ: ZIXI)(FREE stock trend analysis). ZIXI has announced its intention to close its ePrescription business. Earlier Zix’s board of advisors worked for six months to explore the strategic options for...
-
ThinkEquity Upgrades Netezza (NZ) to Buy from Accumulate
Friday, August 28, 2009 - 8:39am | 41Read More...ThinkEquity upgraded Netezza (NYSE: NZ) to Buy from Accumulate. The firm cites expected IT spending and the company's compelling new product cycle for the upgrade. The target was raised to $12 from $8.

